Please assess the completion status of the following clinical trial:

Trial Title: Hexaminolevulinate (HAL) Photodynamic Therapy (PDT) of Cervical Intraepithelial Neoplasia (CIN) Grade 1

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Satisfactory colposcopy examination~* Negative endocervical canal by colposcopy~* Ectocervical CIN1 as verified by local pathologist (biopsy).~* Colposcopical visible lesion at visit 2, before photoactivation~* Written Informed Consent signed~* Age 18 or above~Exclusion Criteria:~* Previous treatment of CIN or invasive disease or suspicion of either micro-invasive or invasive disease~* Malignant cells on cytology or histology~* Atypical glandular cells (AGC) or adenocarcinoma in situ (AIS) on cytology~* Suspicion of endocervical disease on colposcopy~* Current pelvic inflammatory disease, cervicitis, or other gynecological infection as per colposcopy and clinical examination~* Known or suspected porphyria~* Known allergy to hexaminolevulinate or similar compounds (e.g. methyl aminolevulinate or aminolevulinic acid)~* Use of heart pacemaker~* Pregnancy~* Nursing~* Childbirth or miscarriage within six weeks of enrolment - Known~* Participation in other competitive clinical studies either concurrently or within the last 30 days~* Risk of poor protocol compliance~* Not willing to use adequate birth control from screening until last PDT~* Subject is the investigator or any sub-investigator, research assistant, pharmacist, study coordinator, other staff or relative thereof directly involved in the conduct of the protocol.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): HAL suppository (single administration, HAL 100mg), laser illumination (50J/cm2)
- 2 (Type: PLACEBO_COMPARATOR): Placebo suppository (single administration), laser illumination (50J/cm2)
- 3 (Type: NO_INTERVENTION): None
- 4 (Type: ACTIVE_COMPARATOR): HAL ointment (5%, 100mg, single administration), LED diode illumination (50J/cm2)
- 5 (Type: PLACEBO_COMPARATOR): Placebo ointment (single administration), no illumination

Based on this trial design, predict the completion outcome and termination type (if applicable).